VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland. The company's lead product, Lonapegsomatropin, a once-weekly long-acting growth hormone replacement therapy for the treatment of pediatric growth hormone deficiency. It also develops TransCon CNP (navepegritide), a long-acting prod...
Visen Pharmaceuticals reported revenue of 165,000 CNY for fiscal year 2025, and net income of -253.42 million CNY.
Figures from company filings; latest fiscal year ended December 31, 2025.
No profile data available.